Trial Profile

Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer ≥ 2 cm with Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Anastrozole; Palbociclib
Indications Early breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CheckMate 7A8
Sponsors Bristol-Myers Squibb

Most Recent Events

22 May 2024 This trial has been discontinued in Belgium (Global end date: 27 July 2021).
14 Jul 2022 Status changed from discontinued to completed.
26 Aug 2021 Status changed from active, no longer recruiting to discontinued due to adverse change in the risk/benefit.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com